"Right-to-Try" experimental drugs: an overview.

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Medical Ethics and Policy
• Health Informatics

Background:

• The 2018 "Right-to-Try" Act enables patients with life-threatening conditions to access unapproved treatments.
• This legislation presents opportunities for emerging biotechnology and pharmaceutical companies.
• It also raises critical considerations regarding patient safety and drug development.

Purpose of the Study:

• To review the advantages and disadvantages of the Right-to-Try Act.
• To explore the integration of cutting-edge technologies with experimental drug access.
• To analyze the impact on drug development and patient care.

Main Methods:

• Literature review of the Right-to-Try Act and its implications.
• Analysis of current scientific and clinical advancements in experimental therapeutics.
• Examination of synergistic approaches including artificial intelligence (AI) and big data.

Main Results:

• Right-to-Try facilitates early access but poses challenges in risk management.
• Advanced technologies like AI and machine learning can enhance clinical decision-making and data analysis.
• Electronic health records and data refineries are crucial for managing large datasets.

Conclusions:

• The Right-to-Try Act offers a pathway for innovative treatments but requires careful oversight.
• Integrating AI, machine learning, and big data can optimize the use of experimental drugs.
• Data-driven approaches are essential for informed clinical decisions and mitigating risks in early drug access programs.